Should We Use Dialyzable β-Blockers in Hemodialysis?
作者信息
Georgianos Panagiotis I, Eleftheriadis Theodoros, Liakopoulos Vassilios
机构信息
Section of Nephrology and Hypertension, First Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Department of Nephrology, Faculty of Medical Sciences, University of Thessaly, Larissa, Greece.
出版信息
Kidney Med. 2022 Apr 20;4(5):100468. doi: 10.1016/j.xkme.2022.100468. eCollection 2022 May.
Abstract
摘要
相似文献
1
Should We Use Dialyzable β-Blockers in Hemodialysis?我们是否应该在血液透析中使用可透析的β受体阻滞剂？
Kidney Med. 2022 Apr 20;4(5):100468. doi: 10.1016/j.xkme.2022.100468. eCollection 2022 May.
2
β-Blocker Use and Cardiovascular Outcomes in Hemodialysis: A Systematic Review.β受体阻滞剂在血液透析中的应用与心血管结局：一项系统评价
Kidney Med. 2022 Apr 1;4(5):100460. doi: 10.1016/j.xkme.2022.100460. eCollection 2022 May.
3
β-blocker dialyzability and the risk of mortality and cardiovascular events in patients undergoing hemodialysis.β受体阻滞剂的透析率与血液透析患者的死亡率和心血管事件风险。
Nephrol Dial Transplant. 2020 Nov 1;35(11):1959-1965. doi: 10.1093/ndt/gfaa058.
4
Beta-blockers use from the general to the hemodialysis population.β受体阻滞剂在普通人群至血液透析人群中的应用。
Nephrol Ther. 2019 Apr;15(2):71-76. doi: 10.1016/j.nephro.2018.10.003. Epub 2019 Feb 1.
5
Clearance of cardiovascular medications during hemodialysis.血液透析期间心血管药物的清除率。
Curr Opin Nephrol Hypertens. 2016 May;25(3):257-67. doi: 10.1097/MNH.0000000000000216.
6
Differences in the Microbial Composition of Hemodialysis Patients Treated with and without β-Blockers.接受β受体阻滞剂治疗和未接受β受体阻滞剂治疗的血液透析患者的微生物组成差异。
J Pers Med. 2021 Mar 12;11(3):198. doi: 10.3390/jpm11030198.
7
Effect of Beta-Blocker Cardioselectivity on Vascular Refilling in Hemodialysis Patients.β受体阻滞剂心脏选择性对血液透析患者血管再充盈的影响。
Cardiorenal Med. 2021;11(5-6):237-242. doi: 10.1159/000519661. Epub 2021 Nov 16.
8
Beta-blocker prescription and outcomes in hemodialysis patients from the Japan Dialysis Outcomes and Practice Patterns Study.β受体阻滞剂在日本透析结局和实践模式研究中的血液透析患者中的处方和结局。
Nephron Clin Pract. 2009;113(3):c132-9. doi: 10.1159/000232593. Epub 2009 Aug 12.
9
Indoxyl-beta-D-glucuronide and 3-indoxyl sulfate in plasma of hemodialysis patients.
Clin Nephrol. 1996 Apr;45(4):250-6.
10
Cooking Chicken Breast Reduces Dialyzable Iron Resulting from Digestion of Muscle Proteins.烹饪鸡胸肉会降低肌肉蛋白质消化产生的可透析铁。
Int J Food Sci. 2014;2014:345751. doi: 10.1155/2014/345751. Epub 2014 Dec 28.
本文引用的文献
1
β-Blocker Use and Cardiovascular Outcomes in Hemodialysis: A Systematic Review.β受体阻滞剂在血液透析中的应用与心血管结局：一项系统评价
Kidney Med. 2022 Apr 1;4(5):100460. doi: 10.1016/j.xkme.2022.100460. eCollection 2022 May.
2
β-blocker dialyzability and the risk of mortality and cardiovascular events in patients undergoing hemodialysis.β受体阻滞剂的透析率与血液透析患者的死亡率和心血管事件风险。
Nephrol Dial Transplant. 2020 Nov 1;35(11):1959-1965. doi: 10.1093/ndt/gfaa058.
3
Clinical Pharmacokinetics in Kidney Disease: Application to Rational Design of Dosing Regimens.临床药代动力学在肾脏病中的应用：合理设计给药方案。
Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1254-1263. doi: 10.2215/CJN.05150418. Epub 2018 Jul 24.
4
Clinical Pharmacokinetics in Kidney Disease: Fundamental Principles.临床肾脏病药代动力学：基础原理。
Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1085-1095. doi: 10.2215/CJN.00340118. Epub 2018 Jun 22.
5
A Comparative Study of Carvedilol Versus Metoprolol Initiation and 1-Year Mortality Among Individuals Receiving Maintenance Hemodialysis.卡维地洛与美托洛尔起始治疗对维持性血液透析患者 1 年死亡率的比较研究。
Am J Kidney Dis. 2018 Sep;72(3):337-348. doi: 10.1053/j.ajkd.2018.02.350. Epub 2018 Apr 10.
6
-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial.维持性血液透析患者中阻滞剂的可透析性：一项随机临床试验。
Clin J Am Soc Nephrol. 2018 Apr 6;13(4):604-611. doi: 10.2215/CJN.07470717. Epub 2018 Mar 8.
7
Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis.慢性透析患者的高血压流行病学、诊断和管理。
Nat Rev Nephrol. 2016 Oct;12(10):636-47. doi: 10.1038/nrneph.2016.129. Epub 2016 Aug 30.
8
Effectiveness comparison of cardio-selective to non-selective β-blockers and their association with mortality and morbidity in end-stage renal disease: a retrospective cohort study.心脏选择性与非选择性β受体阻滞剂在终末期肾病中的有效性比较及其与死亡率和发病率的关联：一项回顾性队列研究
BMC Cardiovasc Disord. 2016 Mar 25;16:60. doi: 10.1186/s12872-016-0233-3.
9
β-Blocker dialyzability and mortality in older patients receiving hemodialysis.接受血液透析的老年患者中β受体阻滞剂的透析性与死亡率
J Am Soc Nephrol. 2015 Apr;26(4):987-96. doi: 10.1681/ASN.2014040324. Epub 2014 Oct 30.
10
Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial.阿替洛尔或赖诺普利治疗血液透析患者高血压的随机对照试验。
Nephrol Dial Transplant. 2014 Mar;29(3):672-81. doi: 10.1093/ndt/gft515. Epub 2014 Jan 6.
Zotero 插件